Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...

Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ETCompany ParticipantsJennifer Halchak - VP, IRKevin Ali - ...

Organon (NYSE: OGN) today announced its results for the fourth quarter and full year ended December 31, 2024. “In 2024 we achieved our third year of constant currency revenue growth and delivered ...

Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begins in 2028.

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...

MRK provided 2025 adjusted EPS guidance of $8.88 to $9.03, while the giant drugmaker expects sales of $64.1 billion to $65.6 ...

Merck (MRK) reported fourth quarter and full-year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...

Merck shares tumbled Tuesday morning after the drugmaker's soft outlook outweighed fourth-quarter revenue and adjusted ...